VIVANZA.BO · BSE
Vivanza Biosciences Limited
₹1.76
-2.22% (-₹0.04)
Prev. close
₹1.8
Volume
20,493
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Vivanza Biosciences Limited
Vivanza Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India. It offers pharmaceuticals in various categories; injectable products, including antifungals, antibiotics, antivirals, and other products for hospital and clinical use; Vivanza medical gloves for medical and surgical use; therapeutic index injection; and veterinary products and feed. The company was incorporated in 1982 and is headquartered in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jainil Raseshkumar Bhatt
Headquarters
Ahmedabad
Employees
6
Website
vivanzabiosciences.comExchange
View on BSE ↗Key stats
Market cap
₹7.04 Cr
P/E ratio (TTM)
14.7
EPS (TTM)
₹0.12
Beta (1Y · daily vs NIFTY 50)
0.54
Beta (5Y · monthly vs NIFTY 50)
0.07
Shares float
1.61 Cr
EPS · quarter ended Jun 2026
₹0.04
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹9.89 Cr | ₹10.40 Cr | ₹17.81 Cr | ₹27.84 Cr | ₹7.42 Cr | ₹115.91 Cr | |
| EBITDA | ₹60.10 L | ₹74.60 L | ₹1.14 Cr | ₹1.12 Cr | ₹-30.03 L | ₹84.45 L |
| ₹7.50 L | ₹33.30 L | ₹59.83 L | ₹54.73 L | ₹-67.41 L | ₹39.44 L | |
| Diluted EPS | — | — | ₹0.15 | ₹0.01 | ₹-0.17 | ₹0.1 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹22.48 Cr | ₹19.50 Cr | ₹16.45 Cr | ₹22.09 Cr | |
| — | — | ₹8.00 Cr | ₹5.17 Cr | ₹8.65 Cr | ₹10.19 Cr | |
| Stockholders' equity | — | — | ₹4.09 Cr | ₹4.64 Cr | ₹3.96 Cr | ₹4.36 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-94.57 L | ₹2.04 Cr | ₹-2.50 Cr | ₹-2.58 Cr | |
| Investing cash flow | — | — | ₹0 | ₹-3.75 L | ₹-79,000 | ₹-12.40 L |
| Financing cash flow | — | — | ₹1.03 Cr | ₹-1.98 Cr | ₹2.46 Cr | ₹2.65 Cr |
| Capital expenditure | — | — | — | ₹-3.75 L | ₹-79,000 | ₹-12.40 L |
| End cash position | — | — | ₹14.09 L | ₹16.68 L | ₹11.69 L | ₹6.53 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Vivanza Biosciences Limited | ₹7.20 Cr | ₹1.8 | 15.0 | 1.65 | 9.0% | 2.34 | +1461.4% | -13.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 23
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.